× Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our privacy policy


× Important note: This Web site presents preliminary results. We are working non-stop to complete the biocuration as soon as possible.

meta|Evidence - COVID-19

Live meta-analysis and evidence synthesis of potential therapies for COVID19

  Summary of results of all meta-analysis  
tutorial video
En     Fr

Our approach

Latest studies

Arshad (HCQ) , 2020   OBS 3 days ago

hydroxychloroquine vs. control critical risk of bias

  • suggested 66 % decrease in mortality but with a very low degree of certainty due to critical risk of bias

meta-analysis

Arshad (HCQ AZ) , 2020   OBS 3 days ago

hydroxychloroquine plus macrolides vs. control critical risk of bias

  • suggested 71 % decrease in mortality but with a very low degree of certainty due to critical risk of bias

meta-analysis

lopinavir/ritonavir vs. standard of care some concern in risk of bias

    preliminary results given by the way of a press release.

  • inconclusive results for: mortality

preliminary results given by the way of a press release.

meta-analysis

Lagier , 2020   OBS 2 weeks ago

hydroxychloroquine plus macrolides vs. control critical risk of bias

  • suggested 70 % decrease in death, ICU transfer, hospitalization ≥ 10 days but with a very low degree of certainty due to critical risk of bias
  • suggested 51 % decrease in mortality but with a very low degree of certainty due to critical risk of bias
  • suggested 62 % decrease in hospitalization ≥ 10 days but with a very low degree of certainty due to critical risk of bias

meta-analysis

Sbidian (HCQ alone) , 2020   OBS 2 weeks ago

hydroxychloroquine vs. control critical risk of bias

  • inconclusive results for: 28-day mortality

meta-analysis

hydroxychloroquine plus macrolides vs. control critical risk of bias

  • inconclusive results for: 28-day mortality

meta-analysis

RECOVERY dexamethasone unpublished   NCT04381936 3 weeks ago

dexamethasone vs. standard of care NA risk of bias

  • demonstrated 17 % decrease in death

in an exploratory subgroup analysis there was no benefit among patients who did not require oxygen (1.22 [0.86 to 1.75]; p=0.14)

meta-analysis

RECOVERY unpublished   NCT04381936 5 weeks ago

hydroxychloroquine vs. control NA risk of bias

  • inconclusive results for: 28-day death

meta-analysis

Boulware , 2020   NCT04308668 5 weeks ago

hydroxychloroquine vs. placebo low risk of bias

  • inconclusive results for: death; incidence of new illness compatible with Covid-19; hospitalization

meta-analysis

NIH NIAID ACTT-1 , 2020   NCT04280705 2 months ago

remdesevir vs. placebo some concern in risk of bias

  • suggested 32 % increase in recovery
  • suggested 28 % decrease in serious adverse events
  • inconclusive results for: death

meta-analysis

Follow-us

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons